Industry reports
Editor highlights

Search inside this page

Publishers

All regions

Free Market Research Guides to Download

Pathology Analysis & Statistics, January 2014 (p2)

You might be interested in: cancer, breast cancer, prostate cancer, more »

» Purchase Premium Reports

31-80 of about 5 600 reports
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

  • $ 3 500
  • Industry report
  • January 2014
  • by GBI Research

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape Summary GBI Research, has released the ...

  • Industries : Pathology
  • Countries : World
Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, Japan, World, Europe, United States, United Kingdom
Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, Germany, Japan, World, United States
Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, Germany, Japan, World, United States, United Kingdom
Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Japan, World, United States
Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Invega (Schizophrenia) - Forecast and Market Analysis to 2022

Invega (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Invega (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022

Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022

Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Humira (Crohn's Disease) - Forecast and Market Analysis to 2022

Humira (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Humira (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022

Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will ...

  • Industries : Pathology
  • Countries : Canada, World, United States, India, China
Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022

Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022

Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
  • Countries : Canada, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, India, China, Europe
Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022

Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
  • Countries : China, World, Spain, Italy, France, Germany, United States, Canada, India, Europe
Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022

Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will ...

  • Industries : Pathology
  • Countries : Canada, World, Spain, Italy, France, Germany, United States, United Kingdom, India, China, Europe
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech

  • $ 3 295
  • Industry report
  • February 2014
  • by Currentpartnering

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements ...

  • Industries : Pathology
  • Countries : United States
Cardiovascular Partnering Terms and Agreements

Cardiovascular Partnering Terms and Agreements

  • $ 2 995
  • Industry report
  • March 2014
  • by Currentpartnering

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service. The Cardiovascula ...

  • Industries : Pathology
Central Nervous System Partnering Terms and Agreements

Central Nervous System Partnering Terms and Agreements

  • $ 2 995
  • Industry report
  • March 2014
  • by Currentpartnering

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service. The Central Nervous ...

  • Industries : Pathology
Gastrointestinal Partnering Terms and Agreements

Gastrointestinal Partnering Terms and Agreements

  • $ 2 995
  • Industry report
  • March 2014
  • by Currentpartnering

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service. The Gastrointestinal ...

  • Industries : Pathology
Genitourinary Partnering Terms and Agreements

Genitourinary Partnering Terms and Agreements

  • $ 2 995
  • Industry report
  • March 2014
  • by Currentpartnering

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service. The Genitourinary Partnering ...

  • Industries : Pathology

» View Public Reports

About 12 000 reports

The Australian Pharmaceutical Business Brief

  • Industry report
  • April 2014
  • 8 pages
  • by Corporation

... To compare the expenditure of other chronic diseases, particularly chronic diseases that share many of the same risk factors such as ckd [14]. As a result, this investigation will determine and compare ...

U.s. Diabete Sector

April 2014

» Read our Company Profiles

About 200 Companies

GlaxoSmithKline P.L.C.

United States

Novartis Inc.

Switzerland

Pfizer Inc.

United States

GlaxoSmithKline PLC

United Kingdom

Johnson and Johnson

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.